4599.T

Compare

No price history available for this symbol yet.

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Sector

Biotechnology

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2027	$540M	+0.0%	$-22.80	$-22.80–$-22.80	—	1
2028	$541M	+0.2%	$-23.60	$-23.60–$-23.60	—	1
2029	$1.1B	+111.6%	$0.00	$0.00–$0.00	—	0

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

DCF fair valuemodel estimate

Intrinsic value

$86.28

Price

$180.00

Implied downside

-52%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
4599.TStemRIM	$180.00	-1.10%	$11.3B	—
3902.TMedical Data Vision Co., Ltd.	$1684.00	+0.00%	$63.8B	—
4538.TFuso Pharmaceutical Industries,Ltd.	$2231.00	+1.64%	$19.0B	—
4575.TCanBas Co., Ltd.	$735.00	-0.54%	$14.5B	—
4579.TRaQualia Pharma Inc.	$568.00

StemRIM

StemRIM is a biotechnology firm dedicated to developing regenerative medicines aimed at treating severe and challenging diseases. Its product pipeline includes PJ1, a regeneration-inducing medicine based on HMGB1 peptides, which is currently undergoing Phase II clinical trials for a range of conditions such as epidermolysis bullosa, cerebral infarction, osteoarthritis, chronic liver disease, and cardiomyopathy. Beyond PJ1, StemRIM is also advancing PJ2, another regeneration-inducing medicine utilizing novel peptides A and B; PJ3, a biologic protein designed to promote regeneration; PJ4, a device for collecting a patient's own cells for therapeutic purposes; and PJ5, a stem cell-based gene therapy. Established in 2006, StemRIM is headquartered in Ibaraki, Japan.

www.stemrim.com

Employees: 45
IPO / List date: Aug 9, 2019
HQ: JP

Held by traders on TradeandTell

No one on the platform currently holds 4599.T.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in 4599.T as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded 4599.T yet.